Strand Life Sciences Launches Blood Test for Early Cancer Detection
By Rediff Money Desk, New Delhi Nov 30, 2024 16:08
Strand Life Sciences introduces CancerSpot, a blood-based test using methylation profiling for early detection of multiple cancers. The test offers a simple, non-invasive way to identify cancer tumor DNA fragments in blood. This groundbreaking technology aims to improve cancer treatment outcomes...
New Delhi, Nov 30 (PTI) Genomics and bioinformatics firm Strand Life Sciences on Saturday launched a blood-based test for early detection of multiple cancers.
CancerSpot uses latest globally accepted methylation profiling technology to identify cancer tumor DNA fragments.
The test works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood, Strand Life Sciences, a subsidiary of Reliance Industries, said in a statement.
"Cancer in India is emerging as a major cause of morbidity and mortality. It is a source of heavy financial, social and psychological burden on patients, families and communities," Reliance Industries Member of the Board Isha Ambani Piramal stated.
She further said: "Therefore, Strand's novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions."
Piramal said the company is committed to utilising the power of genomics in advancing healthcare and wellness, and improving lives in India, as well as the rest of the world.
"Over our 24-year history, Strand has been a pioneer in genomics, and this is another first for India resulting from a rigorous multi-year research study," Strand Life Sciences CEO and Co-Founder Ramesh Hariharan said.
CancerSpot uses latest globally accepted methylation profiling technology to identify cancer tumor DNA fragments.
The test works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood, Strand Life Sciences, a subsidiary of Reliance Industries, said in a statement.
"Cancer in India is emerging as a major cause of morbidity and mortality. It is a source of heavy financial, social and psychological burden on patients, families and communities," Reliance Industries Member of the Board Isha Ambani Piramal stated.
She further said: "Therefore, Strand's novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions."
Piramal said the company is committed to utilising the power of genomics in advancing healthcare and wellness, and improving lives in India, as well as the rest of the world.
"Over our 24-year history, Strand has been a pioneer in genomics, and this is another first for India resulting from a rigorous multi-year research study," Strand Life Sciences CEO and Co-Founder Ramesh Hariharan said.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
MORE NEWS
Mumbai Property Registrations Rise 5% in...
Property registrations in Mumbai's municipal region rose 5% to over 10,200 units in...
SBI Launches Drive to Activate Inoperative...
State Bank of India (SBI) has launched a nation-wide drive to raise awareness about the...
EPFO Amnesty Scheme: Employers Can Now Deposit...
The EPFO has introduced an amnesty scheme allowing employers to deposit past provident...